BENEMID

LOE Approaching

probenecid

NDAORALTABLETPriority Review
Approved
Apr 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

etzadroxil, a penem antibacterial drug [see Microbiology ] and probenecid, a renal tubular transport inhibitor. Probenecid inhibits OAT3-mediated renal clearance of sulopenem, resulting in increased plasma concentrations of sulopenem .

Clinical Trials (5)

NCT07092813Phase 1Recruiting

Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents

Started Jan 2026
NCT06647810Phase 1Completed

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

Started Nov 2024
15 enrolled
Healthy
NCT06416800Phase 1Completed

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Started Jun 2024
71 enrolled
Healthy Participants
NCT05190744Phase 2Completed

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

Started Sep 2022
36 enrolled
Autosomal Dominant Polycystic Kidney DiseaseNephrogenic Diabetes InsipidusAcquired Nephrogenic Diabetes Insipidus+1 more
NCT03937258Phase 1Completed

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

Started May 2019
12 enrolled
Healthy